Pharmking schreef op 15 mei 2014 07:17:
In the first quarter of 2014, the Company generated revenue from sales of Ruconest of €0.9 million (Q1 2013: €nil)
Costs of revenues amounted to €1.2 million (2013: €nil) including impairments of inventories amounting to €0.4 million, reflecting the low yield from EU sales in combination with the current cost of manufacturing, absent economies of scale. Gross Profits decreased as result of this from €0.5 million to €0.2 million.